INSERM press release!

Our recently published study has been highlighted by INSERM (French National Institute of Health and Medical research) in its press release regarding its engagement in Cancer Research at the occasion of the World Cancer Day (4th of February). Their article (entitled “World Cancer Day: INSERM committed more than ever!") describes three studies with potential implications for care, including ours on the impact of chemotherapy on cell resistance to treatment (performed in collaboration with J.

New publication on cancer in Nature Communications

Excited to share our multidisciplinary research work on the impact of a chemotherapy drug on the behavior of cancer cells published in @NatureComms. This is part of a collaboration launched by JJ. Diaz team at the Center for Cancer Research of Lyon (Centre Léon Bérard) and our team is involved in the study of translation mechanism combining deep sequencing and bioinformatics. Team member involved: J. Ripoll Collaborators: A. David

Funding from the Fondation ARC

Research project on cancer selected for 3 years of funding

INSERM and CNRS press releases about our work!

Both the INSERM and CNRS issued press news on their websites.

FluoRib: impact of chemotherapy on cancer cells' behavior

Overview Chemotherapy is widely used to treat cancer. Some chemical agent is the active principal of the drug. The most used chemical is known as 5-Fluorouracil (5-FU). This project investigates the impact of the 5-FU on the behavior of cancer cells. It tries to determine whether it influences the way these cells build their proteins. Scientific abstract: The chemotherapeutic agent 5-Fluorouracil (5-FU) is the first line treatment for colorectal cancer (CRC) patients.